Invesco Nasdaq Biotechnology ETF (IBBQ)
| Assets | $39.63M |
| Expense Ratio | 0.19% |
| PE Ratio | 18.01 |
| Shares Out | 1.77M |
| Dividend (ttm) | $0.25 |
| Dividend Yield | 1.09% |
| Ex-Dividend Date | Dec 23, 2024 |
| Payout Ratio | 19.65% |
| 1-Year Return | +2.31% |
| Volume | 4,316 |
| Open | 22.60 |
| Previous Close | 22.55 |
| Day's Range | 22.55 - 22.64 |
| 52-Week Low | 20.14 |
| 52-Week High | 24.84 |
| Beta | 0.68 |
| Holdings | 271 |
| Inception Date | Jun 11, 2021 |
About IBBQ
Fund Home PageThe Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index, a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ. IBBQ was launched on Jun 11, 2021 and is issued by Invesco.
Top 10 Holdings
46.73% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 8.50% |
| Amgen Inc. | AMGN | 8.25% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.82% |
| Regeneron Pharmaceuticals, Inc. | REGN | 7.06% |
| AstraZeneca PLC | AZN | 3.89% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 3.40% |
| Illumina, Inc. | ILMN | 2.09% |
| Biogen Inc. | BIIB | 2.07% |
| argenx SE | ARGX | 1.99% |
| Summit Therapeutics Inc. | SMMT | 1.65% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2024 | $0.062 | n/a |
| Sep 23, 2024 | $0.089 | Sep 27, 2024 |
| Jun 24, 2024 | $0.051 | Jun 28, 2024 |
| Mar 18, 2024 | $0.044 | Mar 22, 2024 |
| Dec 18, 2023 | $0.053 | Dec 22, 2023 |
| Sep 18, 2023 | $0.041 | Sep 22, 2023 |
News
IBBQ: This Low-Cost Biotech ETF Comes With Unique Risks
IBBQ is a relatively new U.S. biotech ETF that competes with established peers like IBB and XBI. IBBQ has outperformed both since its June 2021 launch date. However, there are specific risks investors...
IBBQ: Healthcare Dashboard For December
The pharmaceuticals/biotechnology subsector has good value and quality scores. The healthcare equipment industry is significantly overvalued.
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...